Illumina Welcomes Carissa Rollins as Chief Information Officer
SAN DIEGO, March 14, 2022 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) today announced that Carissa Rollins will join the company as Chief Information Officer on March 14, 2022. Rollins brings over 30 years of experience in enterprise technology transformation and digital and consumerization strategy. Rollins will report to CEO Francis deSouza.
Most recently, Rollins was Chief Information Officer at UnitedHealthcare. She was responsible for the technology strategy, roadmap and investments supporting the technology business portfolios of commercial, health and pension, and government programs. Prior to UnitedHealthcare, Rollins held management and executive positions at Gander Mountain, Kohl’s Corporation, Manpower Global and Miller-Coors.
“We are thrilled to have Carissa join the Illumina leadership team,” said Francis deSouza, Illumina president and CEO. “Carissa has an excellent track record of harnessing IT innovation at scale to deliver exceptional customer and employee experiences. We look forward to working together to accelerate the future of personalized medicine for patients around the world.
“I look forward to joining the Illumina team and building on the high performing teams, ensuring key stakeholders have an ever-improving experience with IT services and support.” , shares Rollins. “For me, focusing on our talent, technological innovation will continue to create space to unleash the power of the genome.”
Rollins has served on the YWCA Board of Directors, Minneapolis, and is currently Chairman of the Board. She also sits on the board of directors of the Grand Canyon Conservancy and the advisory board of T-Mobile. Rollins holds a BS in Management Information Systems and an MBA from Marquette University.
Illumina improves human health by unlocking the power of the genome. Our focus on innovation has enabled us to become the world leader in DNA sequencing and chip-based technologies, serving customers in the research, clinical and application markets. Our products are used for applications in life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us at TwitterFacebook, LinkedIn, Instagram and YouTube.
Use of forward-looking statements
This release contains forward-looking statements that involve risks and uncertainties, including the expectation of lower costs associated with storing and managing genomic data costs. Important factors that could cause actual results to differ materially from those set forth in the forward-looking statements include: (i) challenges inherent in developing and launching new products and services; (ii) our ability to deploy new products, services and applications and expand the markets for our technology platforms; and (iii) customer acceptance of our newly launched products, which may or may not meet our and their expectations once deployed, and other factors detailed in our filings with the Securities and Exchange Commission. , including our most recent filings on Forms 10-K and 10-Q, or in information disclosed during public conference calls, the date and time of which are published in advance. We assume no obligation, and do not intend, to update these forward-looking statements, review or confirm analysts’ expectations, or provide interim reports or quarterly progress updates. In progress.
View original content to download multimedia: https://www.prnewswire.com/news-releases/illumina-welcomes-carissa-rollins-as-chief-information-officer-301501578.html